VascuBio Innovation
Revolutionizing Tissue Engineering and Early Diagnosis
VascuBio Innovation, a McGill University spin-off, is committed to transforming drug development and regenerative medicine through advanced bioreactor systems and next-generation point-of-care technologies.
Redefining Regenerative Medicine and Diagnostics
As a dynamic spin-off grounded in academic excellence and innovation, our mission is to redefine the boundaries of regenerative medicine and biomedical diagnostics. We combine deep expertise in engineering, biomaterials, and microfluidics to deliver impactful solutions for healthcare and research.
3D Bioprinting & Advanced Bioreactor Systems
At the heart of VascuBio are our modular bioreactor systems, engineered for precision, versatility, and scalability. Built on years of collaborative research, our technology sets a new standard in tissue engineering—enabling the long-term perfusion, maturation, and analysis of 3D-printed vascular constructs for applications in drug screening, disease modeling, and personalized medicine.
Developing Bioreactors for the Future
At VascuBio, we are not just developing bioreactors; we are shaping the future of regenerative medicine. Our vision is to lead the way in bioreactor and tissue engineering technologies, continually pushing the boundaries of what is possible and driving significant advancements in medical science.
Innovating in Point-of-Care Solutions
The heart of VascuBio lies in our pioneering bioreactor systems. Designed for precision and flexibility, these bioreactors are the culmination of extensive research and innovation. Our technology sets a new standard in the field of tissue engineering, offering unparalleled capabilities in 3D bioprinting
